Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02VFC
|
||||
Former ID |
DAP000452
|
||||
Drug Name |
Cefoxitin
|
||||
Synonyms |
Mefoxin; Mefoxitin; CEFOXITIN SODIUM; Cefoxitin sodium salt; Mefoxin (TN); Cefoxitin (USAN/INN); Cefoxitin sodium (JAN/USP); (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate; (6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(2-thienylacetyl)amino]-3,4-didehydrocepham-4-carboxylate; 3-[(carbamoyloxy)methyl]-7alpha-methoxy-7beta-[(thiophen-2-yl)acetamido]-3,4-didehydrocepham-4-carboxylic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10:A00-B99] | Approved | [536361] | ||
Therapeutic Class |
Antibiotics
|
||||
Company |
Merck & Co
|
||||
Structure |
Download2D MOL |
||||
Formula |
C16H16N3O7S2-
|
||||
Canonical SMILES |
COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)CC3=CC=<br />CS3
|
||||
InChI |
1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/p-1/t14-,16+/m1/s1
|
||||
InChIKey |
WZOZEZRFJCJXNZ-ZBFHGGJFSA-M
|
||||
CAS Number |
CAS 35607-66-0
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
J01DC01
|
||||
SuperDrug CAS ID |
cas=035607660
|
||||
Target and Pathway | |||||
Target(s) | DNA | Target Info | Binder | [536821] | |
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.